These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 28315541)

  • 21. Novel melanoma therapies and their side effects.
    González N; Ratner D
    Cutis; 2016 Jun; 97(6):426-8. PubMed ID: 27416087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune checkpoint inhibitor-induced hypophysitis: clinical and biochemical features.
    Esteves-Ferreira S; Rosinha P
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7925-7932. PubMed ID: 36869230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Superior Pituitary Border Analysis in Immunotherapy-Induced Hypophysitis.
    Pucar D; Boustani AM; Bronen RA; Saperstein L
    Clin Nucl Med; 2018 Apr; 43(4):284-286. PubMed ID: 29401149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Endocrine complications of modern cancer therapy].
    Čáp J
    Vnitr Lek; 2016; 62(9 Suppl 3):45-49. PubMed ID: 27734691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series.
    Lam T; Chan MM; Sweeting AN; De Sousa SM; Clements A; Carlino MS; Long GV; Tonks K; Chua E; Kefford RF; Chipps DR
    Intern Med J; 2015 Oct; 45(10):1066-73. PubMed ID: 26010858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isolated Adrenocorticotropin Deficiency due to Nivolumab-induced Hypophysitis in a Patient with Advanced Lung Adenocarcinoma: A Case Report and Literature Review.
    Ohara N; Ohashi K; Fujisaki T; Oda C; Ikeda Y; Yoneoka Y; Hashimoto T; Hasegawa G; Suzuki K; Takada T
    Intern Med; 2018 Feb; 57(4):527-535. PubMed ID: 29151505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MANAGEMENT OF ENDOCRINE DISEASE: Immune check point inhibitors-induced hypophysitis.
    Albarel F; Castinetti F; Brue T
    Eur J Endocrinol; 2019 Sep; 181(3):R107-R118. PubMed ID: 31311002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center.
    Johnson DB; Friedman DL; Berry E; Decker I; Ye F; Zhao S; Morgans AK; Puzanov I; Sosman JA; Lovly CM
    Cancer Immunol Res; 2015 May; 3(5):464-9. PubMed ID: 25649350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer immunotherapy-associated hypophysitis.
    Castillero F; Castillo-Fernández O; Jiménez-Jiménez G; Fallas-Ramírez J; Peralta-Álvarez MP; Arrieta O
    Future Oncol; 2019 Sep; 15(27):3159-3169. PubMed ID: 31423850
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of toxicities of immune checkpoint inhibitors.
    Spain L; Diem S; Larkin J
    Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypophysitis caused by ipilimumab in cancer patients: hormone replacement or immunosuppressive therapy.
    Lammert A; Schneider HJ; Bergmann T; Benck U; Krämer BK; Gärtner R; Metzner C; Schöfl C; Berking C
    Exp Clin Endocrinol Diabetes; 2013 Nov; 121(10):581-7. PubMed ID: 24122241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Checkpoint inhibitors-induced hypophysitis].
    du Payrat JA; Cugnet-Anceau C; Maillet D; Levy M; Raverot G; Disse E; Borson-Chazot F
    Bull Cancer; 2020 Apr; 107(4):490-498. PubMed ID: 32200950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ipilimumab-induced hypophysitis: review of the literature.
    Araujo PB; Coelho MC; Arruda M; Gadelha MR; Neto LV
    J Endocrinol Invest; 2015 Nov; 38(11):1159-66. PubMed ID: 25957829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pituitary Dysfunction: A Case Series of Immune Checkpoint Inhibitor-Related Hypophysitis in an Emergency Department.
    Miller AH; Brock P; Jim Yeung SC
    Ann Emerg Med; 2016 Aug; 68(2):249-50. PubMed ID: 27451306
    [No Abstract]   [Full Text] [Related]  

  • 35. Ipilimumab-induced hypophysitis: MR imaging findings.
    Carpenter KJ; Murtagh RD; Lilienfeld H; Weber J; Murtagh FR
    AJNR Am J Neuroradiol; 2009 Oct; 30(9):1751-3. PubMed ID: 19474123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.
    Nagai H; Muto M
    Int J Clin Oncol; 2018 Jun; 23(3):410-420. PubMed ID: 29516216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Therapy monitoring and management of adverse events in PD-1/PD-L1 immune checkpoint inhibition].
    Oppel-Heuchel H; Grimm MO
    Urologe A; 2016 May; 55(5):677-90. PubMed ID: 27146870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitis.
    Galligan A; Iravani A; Lasocki A; Wallace R; Weppler AM; Sachithanandan N; Chiang C; Colman PG; Wentworth J; Spain L; Au-Yeung G; Lee B; Kay TWH; Hicks RJ; Sandhu S; Krishnamurthy B
    Front Endocrinol (Lausanne); 2023; 14():1295865. PubMed ID: 38093958
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MRI Findings of Immune Checkpoint Inhibitor-Induced Hypophysitis: Possible Association with Fibrosis.
    Kurokawa R; Ota Y; Gonoi W; Hagiwara A; Kurokawa M; Mori H; Maeda E; Amemiya S; Usui Y; Sato N; Nakata Y; Moritani T; Abe O
    AJNR Am J Neuroradiol; 2020 Sep; 41(9):1683-1689. PubMed ID: 32763900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma.
    Faje AT; Lawrence D; Flaherty K; Freedman C; Fadden R; Rubin K; Cohen J; Sullivan RJ
    Cancer; 2018 Sep; 124(18):3706-3714. PubMed ID: 29975414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.